Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: Results of the German IGLU follow-up study 2001

M. B. Ranke; C. J. Partsch; A. Lindberg; H. G. Dörr; M. Bettendorf; B. P. Hauffa; H. P. Schwarz; O. Mehls; S. Sander; N. Stahnke; H. Steinkamp; E. Said; W. Sippell; H. I. Akkurt; W. Andler; M. Becker; H. J. Böhles; J. Brämswig; O. Butenandt; J. H.H. Enhrich; B. Erxleben; B. Griefahn; A. Grüters; K. Hartmann; F. Haverkamp; W. Hecker; U. Heinrich; G. K. Hinkel; O. Hiort; R. Holl; J. Homoki; G. Horneff; U. Irle; R. Johs; C. Jourdan; E. Keller; J. Kerstan; E. Korsch; J. Kreuder; H. P. Krohn; F. Krull; D. Kunze; M. Lakomek; D. Lenz; U. Leuthold; M. Mix; K. Mohnike; M. Morlot; R. Mühlenberg; H. Müller; M. Pavlovic; K. Rager; W. Rauh; H. J. Rickers; B. Schenk; D. Schnabel; E. Schönau; G. Simic-Schleicher; M. Teufel; W. Tillmann; B. Tittel; U. Tuschy; K. P. Ullrich; W. von Petrikowsky; H. P. Weber; K. Wesseler; R. P. Willig; J. Wintgens; M. Witsch

doi:10.1530/eje.0.1470625

Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: Results of the German IGLU follow-up study 2001

M. B. Ranke^*, C. J. Partsch, A. Lindberg, H. G. Dörr, M. Bettendorf, B. P. Hauffa, H. P. Schwarz, O. Mehls, S. Sander, N. Stahnke, H. Steinkamp, E. Said, W. Sippell, H. I. Akkurt, W. Andler, M. Becker, H. J. Böhles, J. Brämswig, O. Butenandt, J. H.H. EnhrichB. Erxleben, B. Griefahn, A. Grüters, K. Hartmann, F. Haverkamp, W. Hecker, U. Heinrich, G. K. Hinkel, O. Hiort, R. Holl, J. Homoki, G. Horneff, U. Irle, R. Johs, C. Jourdan, E. Keller, J. Kerstan, E. Korsch, J. Kreuder, H. P. Krohn, F. Krull, D. Kunze, M. Lakomek, D. Lenz, U. Leuthold, M. Mix, K. Mohnike, M. Morlot, R. Mühlenberg, H. Müller, M. Pavlovic, K. Rager, W. Rauh, H. J. Rickers, B. Schenk, D. Schnabel, E. Schönau, G. Simic-Schleicher, M. Teufel, W. Tillmann, B. Tittel, U. Tuschy, K. P. Ullrich, W. von Petrikowsky, H. P. Weber, K. Wesseler, R. P. Willig, J. Wintgens, M. Witsch

^*Corresponding author for this work

Clinic of Pediatric and Adolescent Medicine

69 Citations (Scopus)

Abstract

Objectives: We aimed to evaluate the factors influencing true adult height (HT) after long-term (from 1987 to 2000) GH treatment in Design: Out of 347 near-adult (> 16 years) patients from 96 German centres, whose longitudinal growth was documented within KIGS (Pharmacia International Growth Database), 188 (45, × = 59%; bone age > 15 years) were available for further anthropometric measurements. Results: At a median GH dose of 0.88 (10th/90th percentiles: 0.47/1.06) IU/kg per week, a gain of 6.0 (- 1.3/+13) can above the projected adult height was recorded. Variables were recorded at GH start, after 1 year GH, puberty onset, and last visit on GH therapy. At these visits, the median ages were 11.7, 12.7, 14.2, 16.6 and 18.7 years; and median heights, 0.4, 1.1, 1.7, 1.7 and 1.3 SDS (UTS) respectively. Height gain (ΔHT) after GH discontinuation was 1.5 cm. Total ΔHT correlated (P < 0.001) negatively with bone age and HT SDS at GH start, but positively with ΔHT after the first year, ΔHT at puberty onset, and GH duration. Final HT correlated (P < 0.001) positively with HT at GH start, first-year ΔHT, and HT at puberty onset. Body mass index increased slightly (P < 0.05), with values at start and adult follow-up correlating highly (R = 0.70, P < 0.001). No major side effects of GH occurred. Conclusions: GH dosages conceived in the 1980s are safe but too low for most UTS patients. HT gain and height we determined by age and HT at GH start. Height gain during the first year on GH is indicative of overall height gain. After spontaneous or induced puberty, little gain in height occurs.

Original language	English
Journal	European Journal of Endocrinology
Volume	147
Issue number	5
Pages (from-to)	625-633
Number of pages	9
ISSN	0804-4643
DOIs	https://doi.org/10.1530/eje.0.1470625
Publication status	Published - 11.2002

Research Areas and Centers

Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1530/eje.0.1470625

Cite this

Ranke, M. B., Partsch, C. J., Lindberg, A., Dörr, H. G., Bettendorf, M., Hauffa, B. P., Schwarz, H. P., Mehls, O., Sander, S., Stahnke, N., Steinkamp, H., Said, E., Sippell, W., Akkurt, H. I., Andler, W., Becker, M., Böhles, H. J., Brämswig, J., Butenandt, O., ... Witsch, M. (2002). Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: Results of the German IGLU follow-up study 2001. European Journal of Endocrinology, 147(5), 625-633. https://doi.org/10.1530/eje.0.1470625

@article{49cf60e61c784f4bba3ca467a642fd58,

title = "Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: Results of the German IGLU follow-up study 2001",

abstract = "Objectives: We aimed to evaluate the factors influencing true adult height (HT) after long-term (from 1987 to 2000) GH treatment in Design: Out of 347 near-adult (> 16 years) patients from 96 German centres, whose longitudinal growth was documented within KIGS (Pharmacia International Growth Database), 188 (45, × = 59%; bone age > 15 years) were available for further anthropometric measurements. Results: At a median GH dose of 0.88 (10th/90th percentiles: 0.47/1.06) IU/kg per week, a gain of 6.0 (- 1.3/+13) can above the projected adult height was recorded. Variables were recorded at GH start, after 1 year GH, puberty onset, and last visit on GH therapy. At these visits, the median ages were 11.7, 12.7, 14.2, 16.6 and 18.7 years; and median heights, 0.4, 1.1, 1.7, 1.7 and 1.3 SDS (UTS) respectively. Height gain (ΔHT) after GH discontinuation was 1.5 cm. Total ΔHT correlated (P < 0.001) negatively with bone age and HT SDS at GH start, but positively with ΔHT after the first year, ΔHT at puberty onset, and GH duration. Final HT correlated (P < 0.001) positively with HT at GH start, first-year ΔHT, and HT at puberty onset. Body mass index increased slightly (P < 0.05), with values at start and adult follow-up correlating highly (R = 0.70, P < 0.001). No major side effects of GH occurred. Conclusions: GH dosages conceived in the 1980s are safe but too low for most UTS patients. HT gain and height we determined by age and HT at GH start. Height gain during the first year on GH is indicative of overall height gain. After spontaneous or induced puberty, little gain in height occurs.",

author = "Ranke, {M. B.} and Partsch, {C. J.} and A. Lindberg and D{\"o}rr, {H. G.} and M. Bettendorf and Hauffa, {B. P.} and Schwarz, {H. P.} and O. Mehls and S. Sander and N. Stahnke and H. Steinkamp and E. Said and W. Sippell and Akkurt, {H. I.} and W. Andler and M. Becker and B{\"o}hles, {H. J.} and J. Br{\"a}mswig and O. Butenandt and Enhrich, {J. H.H.} and B. Erxleben and B. Griefahn and A. Gr{\"u}ters and K. Hartmann and F. Haverkamp and W. Hecker and U. Heinrich and Hinkel, {G. K.} and O. Hiort and R. Holl and J. Homoki and G. Horneff and U. Irle and R. Johs and C. Jourdan and E. Keller and J. Kerstan and E. Korsch and J. Kreuder and Krohn, {H. P.} and F. Krull and D. Kunze and M. Lakomek and D. Lenz and U. Leuthold and M. Mix and K. Mohnike and M. Morlot and R. M{\"u}hlenberg and H. M{\"u}ller and M. Pavlovic and K. Rager and W. Rauh and Rickers, {H. J.} and B. Schenk and D. Schnabel and E. Sch{\"o}nau and G. Simic-Schleicher and M. Teufel and W. Tillmann and B. Tittel and U. Tuschy and Ullrich, {K. P.} and {von Petrikowsky}, W. and Weber, {H. P.} and K. Wesseler and Willig, {R. P.} and J. Wintgens and M. Witsch",

year = "2002",

month = nov,

doi = "10.1530/eje.0.1470625",

language = "English",

volume = "147",

pages = "625--633",

journal = "European Journal of Endocrinology",

issn = "0804-4643",

publisher = "Bioscientifica Ltd",

number = "5",

}

Ranke, MB, Partsch, CJ, Lindberg, A, Dörr, HG, Bettendorf, M, Hauffa, BP, Schwarz, HP, Mehls, O, Sander, S, Stahnke, N, Steinkamp, H, Said, E, Sippell, W, Akkurt, HI, Andler, W, Becker, M, Böhles, HJ, Brämswig, J, Butenandt, O, Enhrich, JHH, Erxleben, B, Griefahn, B, Grüters, A, Hartmann, K, Haverkamp, F, Hecker, W, Heinrich, U, Hinkel, GK, Hiort, O, Holl, R, Homoki, J, Horneff, G, Irle, U, Johs, R, Jourdan, C, Keller, E, Kerstan, J, Korsch, E, Kreuder, J, Krohn, HP, Krull, F, Kunze, D, Lakomek, M, Lenz, D, Leuthold, U, Mix, M, Mohnike, K, Morlot, M, Mühlenberg, R, Müller, H, Pavlovic, M, Rager, K, Rauh, W, Rickers, HJ, Schenk, B, Schnabel, D, Schönau, E, Simic-Schleicher, G, Teufel, M, Tillmann, W, Tittel, B, Tuschy, U, Ullrich, KP, von Petrikowsky, W, Weber, HP, Wesseler, K, Willig, RP, Wintgens, J & Witsch, M 2002, 'Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: Results of the German IGLU follow-up study 2001', European Journal of Endocrinology, vol. 147, no. 5, pp. 625-633. https://doi.org/10.1530/eje.0.1470625

TY - JOUR

T1 - Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: Results of the German IGLU follow-up study 2001

AU - Ranke, M. B.

AU - Partsch, C. J.

AU - Lindberg, A.

AU - Dörr, H. G.

AU - Bettendorf, M.

AU - Hauffa, B. P.

AU - Schwarz, H. P.

AU - Mehls, O.

AU - Sander, S.

AU - Stahnke, N.

AU - Steinkamp, H.

AU - Said, E.

AU - Sippell, W.

AU - Akkurt, H. I.

AU - Andler, W.

AU - Becker, M.

AU - Böhles, H. J.

AU - Brämswig, J.

AU - Butenandt, O.

AU - Enhrich, J. H.H.

AU - Erxleben, B.

AU - Griefahn, B.

AU - Grüters, A.

AU - Hartmann, K.

AU - Haverkamp, F.

AU - Hecker, W.

AU - Heinrich, U.

AU - Hinkel, G. K.

AU - Hiort, O.

AU - Holl, R.

AU - Homoki, J.

AU - Horneff, G.

AU - Irle, U.

AU - Johs, R.

AU - Jourdan, C.

AU - Keller, E.

AU - Kerstan, J.

AU - Korsch, E.

AU - Kreuder, J.

AU - Krohn, H. P.

AU - Krull, F.

AU - Kunze, D.

AU - Lakomek, M.

AU - Lenz, D.

AU - Leuthold, U.

AU - Mix, M.

AU - Mohnike, K.

AU - Morlot, M.

AU - Mühlenberg, R.

AU - Müller, H.

AU - Pavlovic, M.

AU - Rager, K.

AU - Rauh, W.

AU - Rickers, H. J.

AU - Schenk, B.

AU - Schnabel, D.

AU - Schönau, E.

AU - Simic-Schleicher, G.

AU - Teufel, M.

AU - Tillmann, W.

AU - Tittel, B.

AU - Tuschy, U.

AU - Ullrich, K. P.

AU - von Petrikowsky, W.

AU - Weber, H. P.

AU - Wesseler, K.

AU - Willig, R. P.

AU - Wintgens, J.

AU - Witsch, M.

PY - 2002/11

Y1 - 2002/11

N2 - Objectives: We aimed to evaluate the factors influencing true adult height (HT) after long-term (from 1987 to 2000) GH treatment in Design: Out of 347 near-adult (> 16 years) patients from 96 German centres, whose longitudinal growth was documented within KIGS (Pharmacia International Growth Database), 188 (45, × = 59%; bone age > 15 years) were available for further anthropometric measurements. Results: At a median GH dose of 0.88 (10th/90th percentiles: 0.47/1.06) IU/kg per week, a gain of 6.0 (- 1.3/+13) can above the projected adult height was recorded. Variables were recorded at GH start, after 1 year GH, puberty onset, and last visit on GH therapy. At these visits, the median ages were 11.7, 12.7, 14.2, 16.6 and 18.7 years; and median heights, 0.4, 1.1, 1.7, 1.7 and 1.3 SDS (UTS) respectively. Height gain (ΔHT) after GH discontinuation was 1.5 cm. Total ΔHT correlated (P < 0.001) negatively with bone age and HT SDS at GH start, but positively with ΔHT after the first year, ΔHT at puberty onset, and GH duration. Final HT correlated (P < 0.001) positively with HT at GH start, first-year ΔHT, and HT at puberty onset. Body mass index increased slightly (P < 0.05), with values at start and adult follow-up correlating highly (R = 0.70, P < 0.001). No major side effects of GH occurred. Conclusions: GH dosages conceived in the 1980s are safe but too low for most UTS patients. HT gain and height we determined by age and HT at GH start. Height gain during the first year on GH is indicative of overall height gain. After spontaneous or induced puberty, little gain in height occurs.

AB - Objectives: We aimed to evaluate the factors influencing true adult height (HT) after long-term (from 1987 to 2000) GH treatment in Design: Out of 347 near-adult (> 16 years) patients from 96 German centres, whose longitudinal growth was documented within KIGS (Pharmacia International Growth Database), 188 (45, × = 59%; bone age > 15 years) were available for further anthropometric measurements. Results: At a median GH dose of 0.88 (10th/90th percentiles: 0.47/1.06) IU/kg per week, a gain of 6.0 (- 1.3/+13) can above the projected adult height was recorded. Variables were recorded at GH start, after 1 year GH, puberty onset, and last visit on GH therapy. At these visits, the median ages were 11.7, 12.7, 14.2, 16.6 and 18.7 years; and median heights, 0.4, 1.1, 1.7, 1.7 and 1.3 SDS (UTS) respectively. Height gain (ΔHT) after GH discontinuation was 1.5 cm. Total ΔHT correlated (P < 0.001) negatively with bone age and HT SDS at GH start, but positively with ΔHT after the first year, ΔHT at puberty onset, and GH duration. Final HT correlated (P < 0.001) positively with HT at GH start, first-year ΔHT, and HT at puberty onset. Body mass index increased slightly (P < 0.05), with values at start and adult follow-up correlating highly (R = 0.70, P < 0.001). No major side effects of GH occurred. Conclusions: GH dosages conceived in the 1980s are safe but too low for most UTS patients. HT gain and height we determined by age and HT at GH start. Height gain during the first year on GH is indicative of overall height gain. After spontaneous or induced puberty, little gain in height occurs.

UR - http://www.scopus.com/inward/record.url?scp=0036856397&partnerID=8YFLogxK

U2 - 10.1530/eje.0.1470625

DO - 10.1530/eje.0.1470625

M3 - Journal articles

C2 - 12444894

AN - SCOPUS:0036856397

SN - 0804-4643

VL - 147

SP - 625

EP - 633

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

IS - 5

ER -

Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: Results of the German IGLU follow-up study 2001

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this